Alzheimer’s Disease Global Clinical Trials Review, H1, 2017

All the vital news, analysis, and commentary curated by our industry experts.

$2500

Buy Report

Published: March 15, 2017 Report Code: GDHC4113CTIDB-ST

Report Overview
Key Players
Table of Contents
Table
Figures

GlobalData's clinical trial report, “Alzheimer's Disease Global Clinical Trials Review, H1, 2017" provides an overview of Alzheimer's Disease clinical trials scenario. This report provides top line data relating to the clinical trials on Alzheimer's Disease. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

– The report provides a snapshot of the global clinical trials landscape

– Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status

– The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company

– The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment

– The Report provides enrollment trends for the past five years

– Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to Buy

Assists in formulating key business strategies with regards to investment

Helps in identifying prominent locations for conducting clinical trials which saves time and cost

Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities

Supports understanding of trials count and enrollment trends by country in global therapeutics market

Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials

Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Pfizer Inc
Johnson & Johnson
Eisai Co Ltd
Eli Lilly and Company
F. Hoffmann-La Roche Ltd
AstraZeneca Plc
Novartis AG
GlaxoSmithKline Plc
Allergan Plc
AbbVie Inc

Table of Contents 2

List of Tables 4

List of Figures 5

Report Guidance 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 11

Top Five Countries Contributing to Clinical Trials in Europe 12

Top Countries Contributing to Clinical Trials in North America 13

Top Countries Contributing to Clinical Trials in Middle East and Africa 14

Top Five Countries Contributing to Clinical Trials in Central and South America 15

Clinical Trials by G7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials 16

Clinical Trials by Phase in G7 Countries 18

Clinical Trials in G7 Countries by Trial Status 20

Clinical Trials by E7 Countries: Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials 22

Clinical Trials by Phase in E7 Countries 24

Clinical Trials in E7 Countries by Trial Status 26

Clinical Trials by Phase 28

In Progress Trials by Phase 29

Clinical Trials by Trial Status 30

Clinical Trials by End Point Status 32

Subjects Recruited Over a Period of Time 33

Clinical Trials by Sponsor Type 34

Prominent Sponsors 35

Top Companies Participating in Alzheimer's Disease Therapeutics Clinical Trials 37

Prominent Drugs 39

Latest Clinical Trials News on Alzheimer's Disease 40

Mar 20, 2017: Corium Reports Positive Progress in Pilot Bioequivalence Study of Once-Weekly Corplex Donepezil Patch 40

Mar 16, 2017: QR Pharma Presents New Data on Posiphen in Alzheimer's and Parkinson's Disease at the 13th AD/PD International Conference 40

Mar 15, 2017: Longeveron Achieves Milestone in Groundbreaking Stem Cell Trial for Alzheimer's Disease 40

Mar 10, 2017: Nature Cell Started Commercial Clinical Trials Phase I and II ‘ASTROSTEM,’ Stem Cell Drug for Alzheimers Disease Treatment in US 41

Mar 08, 2017: TGA Regulatory Approval Received for Alzheimer’s Phase II Trial 41

Mar 08, 2017: Diabetes drug shows promise for safely treating, detecting Alzheimers disease 42

Mar 07, 2017: Phase II Clinical Trial for Treatment of Mild Alzheimer's Disease 42

Mar 06, 2017: BrainStorm Strengthens Management Team with Appointment of Ralph Z. Kern, MD, MHSc as Chief Operating Officer and Chief Medical Officer 42

Mar 06, 2017: MorphoSys Partner to Start New Phase 3 Clinical Trials with Gantenerumab in Alzheimer's Disease 43

Mar 01, 2017: Luye Pharma Group: Announcement Approval To Commence Clinical Trials For Rivastigmine Multi-Day Transdermal Patch In Germany 43

Feb 28, 2017: AC Immune Partner Genentech To Start Second Phase 3 Clinical Trial For Alzheimer's Therapy Crenezumab 43

Feb 28, 2017: Accera Announces Results of its First Phase 3 Study in Mild-to-Moderate Alzheimer’s 44

Feb 19, 2017: BIIB076 Moves into Phase 1 for Alzheimer Disease 44

Feb 14, 2017: Merck Announces EPOCH Study of Verubecestat for the Treatment of People with Mild to Moderate Alzheimer's Disease to Stop for Lack of Efficacy 45

Feb 14, 2017: Cantabio Pharmaceuticals to Present Results from Its Tau Protein Targeting Therapeutic Program for the Treatment of Alzheimers Disease at the 13th International Conference on Alzheimer's and Parkinson's Disease 45

Feb 13, 2017: Alzheon to Present New Clinical Data and Analyses for ALZ-801 and Its Active Molecule Tramiprosate at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases 46

Feb 09, 2017: Xanamem research published in prestigious medical journal 46

Feb 03, 2017: Bionomics to Receive Milestone Payment from MSD for Initiation of Phase 1 Clinical Study of Candidate Alzheimer's Treatment 46

Jan 26, 2017: New drug SAK3 may offer hope to Alzheimer's disease patients 47

Jan 25, 2017: ORYZON to present ORY-2001 preliminary top line Phase I clinical data at the 13th International Conference on Alzheimer’s and Parkinson’s Diseases in Vienna, Austria 47

Jan 25, 2017: AbbVie Initiates Phase 2 Clinical Trial Programs for ABBV-8E12, an Investigational Anti-Tau Antibody, in Early Alzheimer's Disease and Progressive Supranuclear Palsy 47

Jan 25, 2017: Voyager Therapeutics Announces Publication of Vectored Anti-Tau Monoclonal Antibody Study in The Journal of Neuroscience 48

Jan 16, 2017: ORYZON Announces Expansion of its Scientific Advisory Board 49

Jan 10, 2017: UK Regulatory Approval for Alzheimer's Disease Clinical Trial – XanADu 49

Jan 09, 2017: Probiodrug announces completion of recruitment for the SAPHIR Phase 2a study of Glutaminyl Cyclase Inhibitor PQ912 in early Alzheimer’s disease patients 49

Jan 09, 2017: NeuroGenetic Pharmaceuticals Completes Phase 1 Clinical Trials for NGP 555 to Treat and Prevent Alzheimer’s Disease; Shown as Safe and Well-Tolerated in Healthy Volunteers 50

Jan 03, 2017: FDA Approval to Commence Alzheimers Disease Clinical Trial 50

Dec 27, 2016: Investigational new drug for Alzheimer's scheduled for first study in humans 50

Clinical Trial Profile Snapshots 52

Appendix 907

Abbreviations 907

Definitions 907

Research Methodology 908

Secondary Research 908

About GlobalData 909

Source 910

Table

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region, 2017* 7

Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8

Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10

Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2017* 11

Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries, 2017* 12

Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries, 2017* 13

Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2017* 14

Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2017* 15

Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 16

Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18

Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20

Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 22

Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24

Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 26

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase, 2017* 28

Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase 2017* 29

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2017* 30

Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2017* 32

Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 33

Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2017* 34

Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 35

Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 37

Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 39

Figures

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Region (%), 2017* 7

Alzheimer's Disease Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2017* 8

Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2017* 10

Alzheimer's Disease Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2017* 11

Alzheimer's Disease Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2017* 12

Alzheimer's Disease Therapeutics Clinical Trials, North America, Top Countries (%), 2017* 13

Alzheimer's Disease Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2017* 14

Alzheimer's Disease Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2017* 15

Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, G7 Countries (%), 2017* 16

Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Phase, 2017* 18

Alzheimer's Disease Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2017* 20

Proportion of Alzheimer's Disease to Central Nervous System Clinical Trials, E7 Countries (%), 2017* 22

Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Phase, 2017* 24

Alzheimer's Disease Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2017* 26

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Phase (%), 2017* 28

Alzheimer's Disease Therapeutics, Global, Clinical Trials In Progress by Phase, 2017* 29

Alzheimer's Disease Therapeutics, Global, Clinical Trials by Trial Status, 2017* 30

Alzheimer's Disease Therapeutics Clinical Trials, Global, by End Point Status, 2017* 32

Alzheimer's Disease Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2012-2016 33

Alzheimer's Disease Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2017* 34

Alzheimer's Disease Therapeutics Clinical Trials, Global, Key Sponsors, 2017* 35

Alzheimer's Disease Therapeutics Clinical Trials, Global, Top Companies by Phase, 2017* 37

Alzheimer's Disease Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2017* 39

GlobalData Methodology 908

Frequently asked questions

Alzheimer’s Disease Global Clinical Trials Review, H1, 2017 standard reports

Currency USD

Single User

$2,500

Can be used by individual purchaser only

Undecided about purchasing this report?

Enquire Before Buying

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise. The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS

Related reports

View more Central Nervous System reports

Pharmaceuticals

New

Antibody-Drug Conjugates (ADC) Overview, Industry Trends, Marketed and Pipeline Products,…

Pharmaceuticals

New

Cell and Gene Therapies in Ophthalmology - Disease Overview, Treatment…

Pharmaceuticals

New

Generic Drugs - Physician Perspective - Thematic Intelligence

Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Alzheimer’s Disease Global Clinical Trials Review, H1, 2017 in real time.

Access a live Alzheimer’s Disease Global Clinical Trials Review, H1, 2017 dashboard for 12 months, with up-to-the-minute insights.
Fuel your decision making with real-time deal coverage and media activity.
Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.

Tell me more

Reports

Reports by Sector

Report Type

Alzheimer’s Disease Global Clinical Trials Review, H1, 2017

Scope

Reasons to Buy

Table of Contents

Table

Figures

Frequently asked questions

Undecided about purchasing this report?

Get in touch to find out about multi-purchase discounts

Related reports